Morrisville, United States
nContact Surgical is a medical device company established in 2005 that focuses on pioneering endoscopic treatments for arrhythmias, particularly atrial fibrillation (AF). The company's flagship offering, the Numeris® Coagulation System with VisiTrax®, stands out for its unique integration of suction, perfusion, and RF energy to create visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart.
Currently, the Numeris® Coagulation System with VisiTrax® is approved for endoscopic coagulation of cardiac tissue in the United States. However, nContact has embarked on IDE clinical studies to explore its efficacy in treating AF in both open and closed chest procedures. Furthermore, in Europe, the Numeris Coagulation System with VisiTrax has obtained CE Mark approval for the coagulation of cardiac tissue in the treatment of AF and atrial flutter.
The latest significant investment in nContact Surgical amounted to $20.00M in Debt Financing, which took place on 13 November 2014 and was facilitated by Hercules Capital. The company operates within the Health Care and Pharmaceutical industries.
